Novo Nordisk A/S annual ebitda for fiscal TTM was $185.8 billion, an increase of 18.6% from $156.7 billion in fiscal 2025. All figures are reported results from public filings — no estimates or projections.
| EBITDA (annual) | TTM → 2026-03-31 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2012-12-31 | 2011-12-31 | 2010-12-31 | 2009-12-31 | 2008-12-31 | 2007-12-31 | 2006-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EBITDA | $185.8B | $156.7B | $147.9B | $114.6B | $76.8B | $65.4B | $59.3B | $54.4B | $51.6B | $52.0B | $51.1B | $46.5B | $37.6B | $35.4B | $30.6B | $24.9B | $21.3B | $17.8B | $14.9B | $12.0B | $11.3B |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| EBITDA (quarterly) | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
|---|---|---|---|---|---|---|---|---|
| EBITDA | $69.2B | $39.7B | $33.3B | $43.6B | $46.0B | $45.8B | $37.4B | $35.7B |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
More NVO metrics: Revenue · Gross Profit · Operating Income · Net Income · EPS · Free Cash Flow · Shares Outstanding
All NVO financial statements → Interactive NVO charts →
About TickerBase · Data methodology & sources